Since TRND was announced only on May 20, 2009, all of the science done this FY was """"""""start-up"""""""" in nature, pertaining to needs assessment and establishing processes for selection of scientific projects to be adopted by TRND and the starting and stopping points for such projects. Specific accomplishments include: 1. Determined governance of TRND and received nominees from numerous ICs for a Trans-NIH Staff Advisory Group (TAG) and an External Expert Panel (EEP). 2. Hired a Senior Scientific Communications Coordinator to act as executive secretary for the TAG and EEP and to coordinate communications. 3. Participated in numerous meetings with companies, academic scientists, and individuals from disease communities interested in learning about TRND. 4. Explored potential partnerships with interested stakeholders in RNDs to seek opportunities to leverage TRND activities.
| Kodippili, Kasun; Hakim, Chady H; Pan, Xiufang et al. (2018) Dual AAV Gene Therapy for Duchenne Muscular Dystrophy with a 7-kb Mini-Dystrophin Gene in the Canine Model. Hum Gene Ther 29:299-311 |
| Huang, Ruili; Southall, Noel; Wang, Yuhong et al. (2011) The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 3:80ps16 |
| Terry, Sharon; Austin, Christopher; Inglese, James et al. (2010) Assay, preclinical, and clinical brick walls and opportunities for system change through GRANDRx. Assay Drug Dev Technol 8:128-34 |
